CML patients with significantly lower probability of PFS were those who carried mutated ASXL1 in both AYAs and adult patients in comparison with patients without mutations supporting the assumption that ASXL1 is the CML-related oncogene [13]. This evidence concerns the gene ASXL1 and chronic myelogenous leukemia, BCR-ABL1 positive.